ReviewCurrent pain and headache reports2023
Low-Dose Initiation of Buprenorphine: A Narrative Review.
Review in Current pain and headache reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- Sociodemographic Characteristics and Drug Use Practices Associated with Fentanyl Use Frequency Among People Who Use Drugs in Rhode Island.Substance use & misuse · 2026Article
- High-dose buprenorphine inductions in hospital settings.American journal of medicine open · 2025Article
- Is buprenorphine maternal dose associated with neonatal opioid withdrawal syndrome severity?The American journal on addictions · 2025Article
- Case report: Successful induction of buprenorphine in medically complex patients concurrently on opioids: a case series at a tertiary care center.Frontiers in pharmacology · 2024Article
- Harm reduction in undergraduate and graduate medical education: a systematic scoping review.BMC medical education · 2023Article
- Transdermal Initiation of Buprenorphine Among Hospitalized Persons: A Retrospective Study.Journal of the Academy of Consultation-Liaison PsychiatryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewOpioid use disorder (OUD) is a chronic disorder in which a person loses control over the use of opioids, develops a compulsive behavior, and defends the use despite knowing the negative consequences. There are numerous treatments for OUD, including buprenorphine. Since it is displacing a full agonist opioid, precipitated withdrawal can occur with standard inductions involving buprenorphine. RECENT
findingsCase reports have noted success with a low-dose initiation of buprenorphine, which is different from typical protocols, relatively limited by adverse effects when patients were recently administered full agonists. A cohort investigation studied the use of a transdermal patch as part of the protocol, which was fairly well tolerated. While ongoing research is being conducted on this topic, recent case studies and smaller cohort studies have demonstrated the feasibility of a trial to treat OUD with low-dose initiation of buprenorphine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.